Technical Analysis for NUVB - Nuvation Bio Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 2.60 | 0.78% | 0.02 |
NUVB closed up 0.78 percent on Friday, April 19, 2024, on 1.11 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 2
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Doji - Bullish? | Reversal | 0.00% | |
| Strong but Oversold | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Strong, Oversold and Reversal Signs | Reversal | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.78% | |
| Narrow Range Bar | Range Contraction | 0.78% | |
| Strong but Oversold | Other | 0.78% | |
| Wide Bands | Range Expansion | 0.78% |
| Alert | Time |
|---|---|
| Down 2 % | about 16 hours ago |
| Outside Day | about 17 hours ago |
| Fell Below Previous Day's Low | about 17 hours ago |
| Down 1% | about 17 hours ago |
| 60 Minute Opening Range Breakdown | about 18 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Prostate Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Prostate Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.1598 |
| 52 Week Low | 0.95 |
| Average Volume | 1,497,539 |
| 200-Day Moving Average | 1.73 |
| 50-Day Moving Average | 2.45 |
| 20-Day Moving Average | 3.09 |
| 10-Day Moving Average | 2.92 |
| Average True Range | 0.29 |
| RSI (14) | 44.75 |
| ADX | 21.85 |
| +DI | 28.07 |
| -DI | 22.90 |
| Chandelier Exit (Long, 3 ATRs) | 3.29 |
| Chandelier Exit (Short, 3 ATRs) | 2.54 |
| Upper Bollinger Bands | 4.01 |
| Lower Bollinger Band | 2.17 |
| Percent B (%b) | 0.23 |
| BandWidth | 59.69 |
| MACD Line | 0.06 |
| MACD Signal Line | 0.19 |
| MACD Histogram | -0.1236 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.99 | ||||
| Resistance 3 (R3) | 3.00 | 2.89 | 2.93 | ||
| Resistance 2 (R2) | 2.89 | 2.79 | 2.88 | 2.90 | |
| Resistance 1 (R1) | 2.74 | 2.73 | 2.82 | 2.73 | 2.88 |
| Pivot Point | 2.63 | 2.63 | 2.66 | 2.62 | 2.63 |
| Support 1 (S1) | 2.48 | 2.53 | 2.56 | 2.47 | 2.32 |
| Support 2 (S2) | 2.37 | 2.47 | 2.36 | 2.30 | |
| Support 3 (S3) | 2.22 | 2.37 | 2.28 | ||
| Support 4 (S4) | 2.21 |
